Skip to main content

Table 1 Covariate adjusted interaction tests between tamoxifen treatment efficacy according to recurrence-free interval and different cell proliferation markers analyzed as continuous linear variables. Co-variables included age (≥ 65 versus < 65), grade (grade 3 versus grade 1–2), tumor size (T3–4 versus T1-T2), HER2 status (positive versus negative), and PgR status (positive versus negative)

From: Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

   

Total follow-up

Follow-up truncated at 6 yearsa

Variable

Variable values

N (events)

p-value

N (events)

p-value

Mitotic count square root

0 to 11

515 (124)

0.16

515 (92)

0.09

Cyclin D1 (continuous)

0 to 100%

432 (105)

0.96

 

Ki67 (continuous)

0 to 100

407 (99)

0.30

CCND1 probeset 1 log 2copy number ratio

−2.43 to 3.36

450 (103)

0.21

CCND1 probeset 2 log2 copy number ratio

−3.46 to 4.00

439 (102)

0.002

  1. aAnalysis performed for mitotic count only, since failure of proportional hazard assumption was observed